None listed
Conditions
Interventions
Intervention1: Quista Isolate: Dosage: 1 sachet 31(g) HQIS-101904 (Chocolate flavor) with 200 ml of water (room temperature) Once daily for 7 days followed by 1 sachet (31g) of HQIS-101904 (Chocolate
Sponsors
The Himalaya Drug Company
Eligibility
Inclusion criteria
Inclusion criteria: 1. Healthy adult volunteers of either sex aged between >=18 to 2. Subjects willing to sign informed consent and follow the study procedure. 3. Has not participated in a similar investigation in the past four weeks. 4. Subjects willing to refrain taking any other nutritional supplement during the study period
Exclusion criteria
Exclusion criteria: 1. Subjects with clinically significant serious cardiovascular, cerebrovascular, respiratory, liver, renal disease, congenital or any other disorder. 2. A known history or present condition of allergic response to pharmaceutical products its components or ingredients in the test product. 3. Pre-existing systemic disease necessitating long-term medications. 4. Genetic and endocrinal disorders. 5. Subjects who refused to sign informed consent. 6. Pregnant and lactating women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence of any adverse or serious adverse events during the study PERIODTimepoint: Screening (Visit 1/ 7 days), day 1 (visit 2), day 7±1 (Visit 3/ Telephonic), day 14 ±1(visit 4) [EOS] along with sensory assessment | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Sensory evaluation before and after the intervention 2. Overall compliance of the subject to the study medicationTimepoint: Screening (Visit 1/ 7 days), day 1 (visit 2), day 7±1 (Visit 3/ Telephonic), day 14 ±1(visit 4) [EOS] along with sensory assessment | — |
Countries
India
Contacts
Public ContactMs Sushma C
The Himalaya Drug Company
Outcome results
None listed